NCT04510311CompletedEarly phase 1
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 10 Aug 2020
- Start date
- 19 Oct 2020
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT04510311
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 32
- From 19 Oct 2020 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:
- Tricyclic antidepressants, which inhibit the norepinephrine transporter: desipramine, amitriptyline, imipramine
- Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine
- Nasal decongestants (some use phenylephrine as the active agent)
- Cocaine (which inhibits the norepinephrine transporter)
- Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter
- Monoamine oxidase inhibitors (MAOI)
- Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine
Other
- Pregnancy or lactation
- Claustrophobia
- Inability to lie flat for 60 minutes
Who the study is looking for
- Current neuroendocrine tumor diagnosis
- Able to lie flat for 60 minutes
- Provision of informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Rogel Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.